Eli Lilly and Co

Eli Lilly and Co(LLY)股票分析

$1,208.740

+43.756 (+3.62%)收盤時

Loading chart…
最高
1,216.714
開盤
1,177.870
成交量加權均價
1,199.90
成交量
3.16M
市值
863.96B
最低
1,174.240
成交金額
3.79B
企業價值/稅息折舊攤銷前利潤(TTM)
19.09

Eli Lilly and Company is a medicine company which discovers, develops, manufactures, and markets products in a single business segment called human pharmaceutical products. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. Its Cardiometabolic Health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients. The Company’s products are sold in approximately 90 countries.

AI 分析 of Eli Lilly and Co (LLY)

買進

Eli Lilly is a good buy right now due to its current price of $1179.27, a strong year-to-date change of +9.16%, and a forward P/E ratio of 24.39, which suggests growth potential. The main risk is the high debt to equity ratio of 162.07%, indicating potential financial strain.

分析師評級(22)

買進
13 買進
8 持有
1 賣出
目前: 1,208.74
最低
950.00
平均
—
最高
—

BofA

2026-10-09

目標價

—

買進

Cantor Fitzgerald

2026-10-08

目標價

—

增持

Morgan Stanley

2026-10-07

目標價

—

增持

JPMorgan

2026-09-28

目標價

—

增持

Guggenheim

2026-09-18

目標價

—

買進

估值指標

Eli Lilly and Co(LLY)目前預期本益比為 24.39,5 年平均預期本益比為 40.89。

預期本益比

低估
5 年均值 P/E
40.89
目前P/E
24.39
高估
51.90
低估
29.88

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
30.14
目前EV/EBITDA
19.09
高估
37.70
低估
22.58

預期股價營收比

合理
5 年均值 P/S
11.55
目前P/S
10.29
高估
13.87
低估
9.24

Alphio AI 對 LLY 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%LLY

$1,138.36

情境價格

基

基準

基準 · 50%LLY

$934.36

情境價格

悲

悲觀

悲觀 · 25%LLY

$711.76

情境價格

持有 LLY 的大戶

C

Corient Private Wealth LP

+ 持有LLY

+52.24%

3個月報酬率

C

Compound Global Advisors, LLC

+ 持有LLY

+12.19%

3個月報酬率

P

PKO Towarzystwo Funduszy Inwestycyjnych SA

+ 持有LLY

+11.89%

3個月報酬率

D

Diversify Wealth Management, LLC

+ 持有LLY

+11.82%

3個月報酬率

R

RBC Europe Limited

+ 持有LLY

+11.62%

3個月報酬率

B

Banque Pictet & Cie SA

+ 持有LLY

+11.36%

3個月報酬率

事件時間軸

2026-10-14 (ET)

10:00:00

UnitedHealth and Others See Notable Gains

2026-10-13 (ET)

07:30:00

Prelude Therapeutics Announces Clinical Trial Collaboration with Eli Lilly

2026-10-09 (ET)

07:00:00

Eli Lilly Announces New Data from TOGETHER-PsO Trial

2026-10-05 (ET)

08:30:00

Gate Bioscience Expands Collaboration with Eli Lilly, Potential Value Exceeds $870M

資訊

LLY 常見問題 —— 由 Alphio AI 解答

Eli Lilly and Company is a medicine company which discovers, develops, manufactures, and markets products in a single business segment called human pharmaceutical products. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. Its Cardiometabolic Health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients. The Company’s products are sold in approximately 90 countries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Eli Lilly is a good buy right now due to its current price of $1179.27, a strong year-to-date change of +9.16%, and a forward P/E ratio of 24.39, which suggests growth potential. The main risk is the high debt to equity ratio of 162.07%, indicating potential financial strain.

22 analysts cover LLY: 13 rate it Buy, 8 Hold and 1 Sell. The average price target is 1,192.

RektUrchin20 小時前

Rotation into defensive sectors like healthcare this morning. Here's $LLY, which continues to set up constructively.

展開
ScalpWalker2026/9/30

$NVO $LLY Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro - Reuters

展開
0xLunarbazaar2026/9/21

$SPY $DKNG $LLY $PSKY $VLVLY 1) In a post on Truth Social, President Trump states: "...I will be announcing, in the near future, the AI 'Czar' - Only High I.Q. individuals need apply! AI is the next Industrial Revolution, or Internet, but will be even larger and more impactful, possibly as much as 25% of our Country's GDP. We are leading China, and the rest of the World, and I intend to keep it that way!" 2) DraftKings (DKNG) puts customer betting records into a machine learning model to find out who is most likely to make losing bets, Alex Klavens, Walt Bogdanich and Jenny Vrentas of New York Times report. The company uses data science to target losing gamblers with promotions that encourage more betting, six former employees told the Times. 3) Some emerging scientific research points to an increased risk for GLP-1 patients to develop nonarteritic anterior ischemic optic neuropathy, or vision loss, Alex Janin of Wall Street Journal reports. GLP-1 developers Novo Nordisk (NVO) and Eli Lilly (LLY) face lawsuits from patients claiming the medications caused NAION, the Journal adds. 4) Paramount (PSKY) and states looking to block its acquisition of Warner Bros. (WBD) could settle as soon as this week, Jody Godoy of Reuters reports, citing sources familiar with the matter. A commitment on the number of movie releases is among the terms of the settlement, the sources added. 5) The Board of Directors of Volvo Cars (VLVLY) has appointed Klaus Zellmer as President and Chief Executive Officer. Klaus Zellmer will assume the position no later than 1 October 2027. Hakan Samuelsson will, together with the Board, ensure a seamless transition. Klaus Zellmer most recently served Chairman of the Board of Management and CEO of Skoda Auto, a Volkswagen (VWAGY) company.

展開
0xLunarbazaar2026/9/19

$LLY $NVO Lilly and Novo face lawsuits over GLP-1 vision loss risk, WSJ says. Some emerging scientific research points to an increased risk for GLP-1 patients of developing nonarteritic anterior ischemic optic neuropathy, or vision loss, Alex Janin of the Wall Street Journal reports. GLP-1 developers Novo Nordisk (NVO) and Eli Lilly (LLY) face lawsuits from patients claiming the medications caused NAION, the Journal adds. Evidence of the vision loss risk is mixed and not clear enough to say whether or how the drugs cause the condition, doctors and researchers said, according to the Journal.

展開
註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始